

# Lupin launches blood cancer generic in US

The launched drug is a bioequivalent of BMS's Sprycel tablets, which has an estimated moving annual turnover (MAT) of \$ 930 million in the US.



Mumbai: Drugmaker Lipin Limited has announced the launch of dasatinib tablets, a blood cancer therapy in the United States.

The launched drug is a bioequivalent of Bristol-Myers Squibb's Sprycel

tablets, and indicated for the treatment of multiple blood cancer indications.

Lipin has developed the product in partnership with Pharmascience Inc.

According to IQVIA, as of october 2025, the drug has an estimated moving annual turnover (MAT) of \$ 930 million in the US.

## News Sources:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/lupin-launches-blood-cancer-generic-in-us/127873547>